GATA-3 expression and its correlation with prognostic factors and survival in canine mammary tumors

Introduction The transcription factor GATA-3 plays a significant role in mammary gland development and differentiation. Recent studies on human oncology have demonstrated its association with favorable pathologic factors in breast cancer. Canine mammary tumours, proposed as comparative and translational study models, have epidemiological, clinical, biological, and genetic characteristics similar to those of human breast cancers. Methods Here, we evaluated the frequency of GATA-3 expression in mammary tumors of dogs and its relationship with prognostic factors and survival. Tumor samples were obtained from 40 female dogs and grouped according to histological type into benign tumors (n = 10), carcinoma in mixed tumors (CMTs) (n = 20), and aggressive tumors (n = 10). CMTs were further separated according to histological grade, and data on clinical staging and diagnosis, histopathological grading, and survival rate were collected. Results GATA-3 and estrogen receptor (ER) expression were higher in benign and well-differentiated carcinomas than in aggressive tumors, which showed greater Ki-67 expression. The expression rate of ER in the studied groups was equivalent to that of GATA-3. We identified a strong positive correlation between GATA-3 and ER expression frequencies and a negative correlation between those of GATA-3 and Ki-67. There were associations between GATA-3 (p < 0.001), Ki-67 (p = 0.003), tumor size (p < 0.001), clinical stage (p = 0.002), lymph node metastasis (p < 0.001), and histological grade (p < 0.001) by univariate survival analysis. The parameters ER (p = 0.015) and GATA-3 (p = 0.005) also influenced survival in a multifactorial manner. Discussion Kaplan–Meier analysis of survival curves validated our previous findings that dogs with GATA-3 expression in ≥79.4% of cells had significantly higher survival rates (p < 0.001). The performance analysis showed that the expression of GATA-3 in ≥79.4% of cells effectively predicted survival or death in dogs with mammary tumors. Collectively, these results suggest that GATA-3 can be a relevant marker in the study of mammary tumor progression and has potential as a prognosis marker for predicting outcomes in canine mammary tumors.

[1]  A. Estrela-Lima,et al.  Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma , 2022, Animals : an open access journal from MDPI.

[2]  R. Laufer-Amorim,et al.  Caveolin-1, GATA-3, and Ki67 expressions and their correlation with pathological findings in canine bladder urothelial carcinoma , 2022, Frontiers in Veterinary Science.

[3]  O. Witkowska-Piłaszewicz,et al.  The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors , 2022, Veterinary sciences.

[4]  F. Carvalho,et al.  Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas. , 2022, European journal of breast health.

[5]  Hui Zhang,et al.  Adrenal Gland Metastasis of Breast Invasive Mucinous Carcinoma: A Rare Case Report and Review of Literature , 2022, Case Reports in Oncology.

[6]  L. Coutinho,et al.  Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer , 2021, Cancers.

[7]  U. Miskad,et al.  Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer. , 2021, Breast disease.

[8]  Ê. Ferreira,et al.  Consensus Regarding the Diagnosis, Prognosis and Treatment of Canine and Feline Mammary Tumors - 2019 , 2020 .

[9]  S. Bektaş,et al.  The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast , 2020, AntiCancer Research.

[10]  T. D. Barral,et al.  Hyperresistinemia in Obese Female Dogs With Mammary Carcinoma in Benign-Mixed Tumors and Its Correlation With Tumor Aggressiveness and Survival , 2020, Frontiers in Veterinary Science.

[11]  G. Tse,et al.  Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors , 2020, Breast Cancer Research and Treatment.

[12]  L. Farahmand,et al.  Breast cancer: Biology, biomarkers, and treatments. , 2020, International immunopharmacology.

[13]  T. Iwamoto,et al.  Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. , 2020, Chinese clinical oncology.

[14]  R. Serakides,et al.  Triple-negative mammary carcinoma in two male dogs , 2020, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[15]  M. Król,et al.  Current biomarkers of canine mammary tumors , 2018, Acta Veterinaria Scandinavica.

[16]  Y. Ho,et al.  The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer. , 2018, Human pathology.

[17]  G. Tse,et al.  GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer , 2018, Breast Cancer Research and Treatment.

[18]  Ê. Ferreira,et al.  Consensus regarding the diagnosis, prognosis and treatment of canine mammary tumors: Benign mixed tumors, carcinomas in mixed tumors and carcinosarcomas , 2017 .

[19]  Anton Belousov,et al.  Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors , 2017, Breast Cancer Research and Treatment.

[20]  M. Campone,et al.  Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance , 2017, Breast Cancer Research and Treatment.

[21]  B. Diaz,et al.  Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules , 2017, PloS one.

[22]  Hardik S. Chhatrala,et al.  Prognostic implication of GATA3 gene mutation on survival in invasive ductal carcinoma of the breast. , 2017 .

[23]  F. Queiroga,et al.  A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs , 2016, BioMed research international.

[24]  Florenza Lüder Ripoli,et al.  Hormone Receptor Expression Analyses in Neoplastic and Non-Neoplastic Canine Mammary Tissue by a Bead Based Multiplex Branched DNA Assay: A Gene Expression Study in Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Samples , 2016, PloS one.

[25]  Yan Wang,et al.  Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. , 2015, Cancer cell.

[26]  S. Efroni,et al.  Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer , 2014, Breast Cancer Research.

[27]  N. Shikata,et al.  Similarity of GATA-3 Expression between Rat and Human Mammary Glands , 2014, Journal of toxicologic pathology.

[28]  M. Walsh,et al.  GATA3: A promising marker for metastatic breast carcinoma in serous effusion specimens , 2014, Cancer cytopathology.

[29]  Markku Miettinen,et al.  GATA3: A Multispecific But Potentially Useful Marker in Surgical Pathology A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors , 2014, The American journal of surgical pathology.

[30]  Jason Wang,et al.  GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. , 2013, Human pathology.

[31]  J. Shu,et al.  Induction of Pluripotency in Mouse Somatic Cells with Lineage Specifiers , 2013, Cell.

[32]  G. Cassali.  Comparative mammary oncology: canine model , 2013, BMC Proceedings.

[33]  Z. Werb,et al.  GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression , 2013, Nature Cell Biology.

[34]  V. Theodorou,et al.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility , 2013, Genome research.

[35]  F. Berry,et al.  BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers , 2012, Oncogene.

[36]  A. Teixeira-Carvalho,et al.  Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers , 2012, Breast Cancer Research and Treatment.

[37]  Wei Shi,et al.  Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14 , 2011, Molecular and Cellular Biology.

[38]  A. Oshima,et al.  GATA3 Inhibits Lysyl Oxidase Mediated Metastases of Human Basal Triple-Negative Breast Cancer Cells , 2011, Oncogene.

[39]  V. Zappulli,et al.  Development, Anatomy, Histology, Lymphatic Drainage, Clinical Features, and Cell Differentiation Markers of Canine Mammary Gland Neoplasms , 2011, Veterinary pathology.

[40]  Steve Horvath,et al.  Higher levels of GATA3 predict better survival in women with breast cancer. , 2010, Human pathology.

[41]  R. Weigel,et al.  GATA-3 as a marker of hormone response in breast cancer. , 2009, The Journal of surgical research.

[42]  Brian J. Wilson,et al.  GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis , 2009, Oncogene.

[43]  F. Bertucci,et al.  Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer , 2009, Breast Cancer Research.

[44]  J. Palazzo,et al.  The significance of GATA3 expression in breast cancer: a 10-year follow-up study. , 2009, Human pathology.

[45]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[46]  T. Nielsen,et al.  GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value , 2008, Cancer Epidemiology Biomarkers & Prevention.

[47]  F. A. R. Sueiro,et al.  Avaliação da caspase-3 e Ki-67 como marcadores prognósticos nas neoplasias mamárias em cadelas , 2007 .

[48]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2006, Breast Cancer Research and Treatment.

[49]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[50]  M Greiner,et al.  A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. , 1995, Journal of immunological methods.

[51]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[52]  I Iu IUDIN,et al.  [Tumors of the mammary gland]. , 1955, Meditsinskaia sestra.

[53]  A. Osunkoya,et al.  GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. , 2016, Human pathology.

[54]  Sara A. Grimm,et al.  GATA3 in Breast Cancer: Tumor Suppressor or Oncogene? , 2015, Gene expression.

[55]  Suguna Rao,et al.  Prognostic Value of Ki 67 Proliferation Antigen in Canine Malignant Mammary Gland Tumours , 2011 .

[56]  N. Lackey,et al.  Making Sense of Factor Analysis , 2003 .

[57]  I. Ellis,et al.  Prognostic factors in invasive carcinoma of the breast. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).